Related Experiment Videos
[Ritalin: a stimulating drug in the treatment of children with minimal brain dysfunction (MBD)]
B C Flapper1, H M Koopman, A Heltzel
1Buitenkliniek Noordwijk, afd. Kindergeneeskunde Academisch Ziekenhuis Leiden.
Insights
Methylphenidate (Ritalin) can enhance therapy for children with Minimal Brain Dysfunction (MBD). A procedure was developed to determine Ritalin
Area of Science:
- Pediatric Neurology
- Child Psychiatry
Context:
- Children with Minimal Brain Dysfunction (MBD) exhibit vulnerabilities requiring comprehensive therapeutic approaches.
- Standard treatments including behavior modification, psychotherapy, and family therapy are not universally effective for all MBD cases.
- Some children with MBD may benefit from adjunctive psychotropic medication.
Purpose:
- To describe a systematic procedure for evaluating the efficacy of methylphenidate (Ritalin) as an adjunct therapy for children with MBD.
- To assess the impact of Ritalin on therapeutic outcomes in a pediatric population with MBD.
Summary:
- Eight children diagnosed with MBD participated in the evaluation.
- Methylphenidate (Ritalin) demonstrated improved therapeutic potential in seven out of eight participants over an extended period.
- Optimal therapeutic dosages of Ritalin were individually determined and found to be relatively low (0.4-0.8 mg/kg/day).
Impact:
- The study suggests Ritalin can be a valuable therapeutic option for select children with MBD, enhancing treatment possibilities.
- The described procedure offers a practical framework for multidisciplinary teams to assess Ritalin's effectiveness in managing childhood behavioral and learning problems.
- Further discussion on the pharmacological properties of Ritalin and its effects in MBD is warranted.
Abstract:
Children with Minimal Brain Dysfunction (MBD) are vulnerable in society. Therapy consists of a combination of behaviour modification techniques, function training, psychotherapy, family therapy and counseling of parents and teachers. This way of treatment is not appropriate for all children with MBD. Some of them need additional therapy with a psychotropic drug e.g. methylphenidate (Ritalin). We describe a procedure to establish, whether Ritalin improves the therapeutic impact in a specific child. Eight children enrolled the program. In seven Ritalin improved the therapeutic possibilities for a longer period of time. The dose for an optimal therapeutic effect varied individually, and was relatively low (0.4-0.8 kg/kg/dg). The hypothesis concerning the effect of psychotropic drugs in MBD and the pharmacological properties of Ritalin are discussed. We believe this procedure to be applicable in any multidisciplinary setting, experienced with behavioural and learning problems in childhood.